Click to edit Master /tle style. Cardiovascular Toxicity in Renal Cell Carcinoma Pa/ents
|
|
- Gyles Taylor
- 6 years ago
- Views:
Transcription
1 Click to edit Master /tle style Cardiovascular Toxicity in Renal Cell Carcinoma Pa/ents Bernhard J. Eigl MD FRCPC Medical Oncologist, BC Cancer Agency Clinical Associate Professor, University of Bri/sh Columbia Provincial Director, Clinical Trials
2 Click to edit Master /tle style Disclosures Consultant: Pfizer, Sanofi, Janssen, Roche, AstraZeneca Research funding: Pfizer, Janssen Educa/onal support: Roche
3 Click to edit Master /tle style Objec/ves Gain general understanding of first- line treatment op/ons for RCC Gain understanding of cardiac toxici/es of TKIs Mechanism Relevance Management
4 RCC Overview The disease More than 200,000 new cases of RCC worldwide annually RCC incidence has been rising by 2% per year for the past 6 decades Approx. 25% of RCC pa/ents present with metasta/c disease Treatment prior to 2005 Cytokine based therapies had low efficacy, median PFS 3-5 months, median OS 13 months Since targeted agents FDA- approved for treatment of RCC Outcomes (survival, QOL) have greatly improved
5 Suni.nib vs. Interferon Alfa in mrcc Suni/nib Median: 11 months IFN Median: 5 months Motzer NEJM 2007; JCO 2009
6 Impact of new agents on BC pa.ent survival Group B+C: first- /second- line SuniBnib 1 year OS 75% Group A: IFN alone 1 year OS 40% Log rank p<0.0001
7 First- line Treatment of mrcc: Current Op.ons Study ORR, % Median PFS, mo* Median OS, mo* Sunitinib vs IFN-α 1 47 vs. 12 Bevacizumab + IFN-α vs IFN-α 2 31 vs. 13 Bevacizumab + IFN-α vs IFN-α vs Pazopanib vs placebo 6 32 vs vs. 5 P < vs. 5.4 P = vs. 5.2 P = vs. 4.2 P = vs 21.8 P = vs P = vs P = vs P = Pazopanib vs Sunitinib 7 31 vs vs. 9.4 noninferior 28.4 vs 29.3 noninferior *Intent to treat analysis 1. Motzer RJ et al. J Clin Oncol. 2009; 2. Escudier B et al. Lancet Rini B et al. J Clin Oncol. 2008; 4. Escudier B et al. J Clin Oncol. 2009; 5. Hudes G et al. N Engl J Med Sternberg C et al. J Clin Oncol. 2010; Motzer et al NEJM 2013
8 COMPARZ Study Key Eligibility Criteria Advanced/metasta/c RCC Clear- cell histology No prior systemic therapy Measurable disease (RECIST 1.0) KPS 70 Adequate organ func/on Stra/fica/on factors: Karnogsy Performance Status (KPS; vs ) Prior nephrectomy (yes vs. no) N=1110 Randomised 1:1 Baseline lactate dehydrogenase (LDH; >1.5 vs. 1.5 x ULN) Pazopanib 800 mg OD ConBnuous dosing SuniBnib 50 mg OD 4 wk on/2 wk off 1. Motzer R, et al. ESMO 2012 oral presenta/on; abstract LBA8_PR.
9 COMPARZ: Suni.nib and Pazopanib are only real first line op.ons 1. Motzer R, et al. NEJM 2013
10 Most common adverse events 30% 1 (treatment-emergent) Pazopanib (n = 554) % Sunitinib (n = 548) % Adverse Event All Grades All Grades Any event a >99 >99 Diarrhea Fatigue Hypertension Nausea Decreased appetite ALT increased Hair colour changes Hand-foot syndrome Taste alteration Thrombocytopenia a 2% of pa/ents in pazopanib arm and 3% of pa/ents in suni/nib arm had grade 5 adverse events Blue Highlight: Risk greater for suni/nib and 95% CI for rela/ve risk does not cross 1 Yellow highlight: Risk greater for pazopanib and 95% CI for rela/ve risk does not cross 1 1. Motzer R, et al. ESMO 2012 oral presenta/on; abstract LBA8_PR.
11 Evolu.on of Overall Survival (OS) with Targeted Agents in mrcc Median OS (Months) Before Targeted Agents Treatment expectations in mrcc have evolved from short term palliation to long-term treatment/survival and therefore toxicities! Era of Targeted Agents Coppin C, et al. Cochrane Collab. 2006;2:CD001425; 2. Escudier B, et al. N Engl J Med. 2007;356: ; 3. Bayer Healthcare. Nexavar (sorafenib) Summary of Product Characteristics, 2008; 4. Escudier B, et al. Lancet. 2007;370: ; 5. Motzer RJ, et al. J Clin Oncol. 2009;27:
12 VEGF Mayor, S. CancerWorld e- Grand- Round (2015)
13 Cardiac Toxici.es of mrcc Therapies Hypertension Myocardial Dysfunc/on ECG changes Thromboembolic events Friday 8:00 Dr. M. Mauro
14 Hypertension
15 Mechanisms of hypertension (HTN) induced by angiogenic inhibitors: the therapeutic low free vascular endothelial growth factor (VEGF) activity contributes to the increase of systemic vascular resistances as a result of vascular rarefaction and downregulation of nitric oxide production, dysregulation of renal endothelial cells and podocyte VEGF expression leading to thrombotic microangiopathy and thereby HTN. H. Izzedine et al. Ann Oncol 2009;20:
16 An.angiogenic Agent- related Hypertension Agent All Grades Grade 3/4 Bevacizumab 9% 1% Pazopanib 13% <1% Sorafenib 17% 4% Sunitinib 30% 17% Axitinib 27% 15% Cediranib 16% 19% NS = not specified l Class effect l Often does not require dose reduction l Regular monitoring of blood pressure is important DiLorenzo G, et al. Eur Urol 2011; Veronese ML, et al. J Clin Oncol. 2006;24: ; Sica DA. J Clin Oncol. 2006;24:
17 Suni.nib mediated hypertension Can be rapid onset Close (home) monitoring and interven/on important Azizi N. et al, NEJM 2008
18 Hypertension - Management Kollmannsberger et al. CUAJ 2007
19 But, hypertension is likely a biomarker of an.tumor efficacy In a retrospec/ve analysis, suni/nib- associated HTN was associated with improved clinical outcome HTN was a significant independent predictor of survival Probability of overall survival With HTN (n=441) Median OS, 30.5 months Without HTN (n=93) Median OS, 7.8 months P< Time (months) Patients should be monitored in the clinic for HTN and treated as necessary Use of anti-htn agents did not reduce sunitinib antitumor activity These findings warrant further study and validation in prospective clinical trials Rini B et al IKCS 2009
20 Suni.nib: Toxicity and Efficacy Toxicity in Sunitinib Study (N pts) PFS (mons) P value Hypertension Hand Foot Syndrome Pooled analysis of trials (544) Pooled analysis of trials (770) 12.5 vs 2.5 P< vs. 8.3 P<0.001 Hypothyroidism Retrospective (50) 21.7 vs 14.2 P<0.001 Rini et al JNCI 2011 Michaelson et al GU Cancers Symp 2011 Abstr 320 Pinto et al GU Cancers Symp 2012 Abstr 466
21 Dose intensity and survival (a digression) COMPARZ told us Pazo is non- inferior to suni/nib (4 weeks on: 2 weeks off) Toxicity is beser (assessed at day 28 of 6 week cycle) BUT: if toxicity correlates with response, are we dosing suni/nib right?
22 Sunitinib Dose Response Relationship Probability of a response Mean 95% CI p=0.023 for AUC AUC sunitinib (ug hr/ml) Fraction pts surviving OS in mrcc High AUC (n=120) Low AUC (n=119) l Inhibition of VEGFR and PDGFR phosphorylation in tumors is doseand time-dependent l Sunitinib exposure is a function of dose and individual clearance l Highest sunitinib exposure resulted in highest probability of response l Higher sunitinib exposure resulted in improved survival Mendel DB, et al. Clin Cancer Res. 2003;9: Houk BE, et al. J Clin Oncol. 2007;25(Suppl 18s):5027 (Abstract) Historical placebo median Time (days) 22
23 Phase II study of individualized sunitinib as first-line therapy for metastatic clear cell renal cell cancer Bjarnason GA, Knox JJ, Kollmannsberger C, Soulières D, Ernst S, Canil C, Winquist E, Zalewski P, Hotte, S, North S, Heng DY, Macfarlane RJ, Czaykowski P, Venner P, Basappa NS. Patients entered in 13 Cancer Centers in Canada: Toronto, Edmonton, London, Vancouver, Ottawa, Halifax, Calgary, Oshawa, Hamilton, Montréal, Kingston and Winnipeg Supported by a Pfizer Investigator Initiated Research Grant to Dr. Bjarnason Bjarnason et al ASCO 2015
24 Dose/schedule allocation of patients during first and subsequent Rx cycles Toxicity evaluation after 2 weeks on first course Subsequent Cycles First cycle Grade-2 toxicity: Stop Rx for 7 d* Grade-2 tox before 4 weeks: Stop Rx for 7 d* Modify dose/schedule DL-1: Pts than cannot take 50 mg for 28 d - 50 mg individualized # of days / 7 days off DL-2: Pts than cannot take 50 mg for 7 d mg individual. # of days / 7 days off DL-3: Pts than cannot take 37.5 mg for 7-25 mg individualized # of days / 7 days off Grade-1 toxicity: Continue Rx Toxicity evaluation after 4 weeks on first course Grade-1 tox At 4 weeks: Stop Rx for 7 d* Escalate dose DL+1: 62.5 mg 14/7 DL+2: 75.0 mg 14/7 Grade-2 tox At 4 weeks: Stop Rx for 7 d* Reduce off-rx time to 7d* DL+: 50mg 28/7d Individually maximize days on Rx during conbnued therapy based on toxicity * Or until toxicity has resolved Bjarnason et al ASCO 2015
25 Response and PFS* for 108 evaluable patients Study OZM 42 EFFECT COMPARZ Drug Individualized Sunitinib Sutent standard dose Axitinib vs. Sorafenib Phase-III 1 st line Sunitinib Pazopanib Axitinib data N CR % 3.9 (n=4) 0 <1 < 1 0 PR % 44.1 (n=45) CR+PR % 48.0 (n=49) SD % 41.2 (n=42) CR+PR+SD 89.2 (n=74) PD % 10.8* (n=11) PFS (mo) Pending* % CI /102 (43.1%) evaluable pts still on therapy* COMPARZ and Axitinib pts had better prognostic factor Bjarnason et al ASCO 2015
26 Individualized therapy = Personalized therapy for all n Safe and feasible in a multicenter setting w An effective way to manage toxicity n Responses are among the best for any TKI in RCC w Implications for dosing of Sutent in other indications and other TKI s w Potential use in combinations with immunotherapy n Associated with improved dose intensity w Individualizing days on treatment overcomes oral dosing limitations w PK data pending. n Compensates for other variables w Diet / Drug interactions, gender, declining AUC over time, SNP s n Empowers patients to take an active role w Understand well the concept of toxicity vs. activity w More receptive to moderate toxicity Bjarnason et al ASCO 2015
27 Myocardial Dysfunc.on
28 Mechanism Force T, et al. Nat Rev Cancer 2007
29 An.angiogenic Agent- related LVF Agent All Grades Grade 3/4 Bevacizumab 1-6% <1% Pazopanib 13% <1% Sorafenib 4% 0% Sunitinib 13% 3% NS = not specified l CRDC Type II l Usually reversible l TKI treatment can continue (with dose modification) if CHF is managed DiLorenzo G, et al. Eur Urol 2011; Hall P, et al. JACC: Heart Failure 2013; Szmit S, et al. Acta Oncologica 2009.
30 Suni.nib and CHF Meta- analysis of available phase II and III studies (not only RCC) N=6935 Incidence of CHF: all- grade = 4.1%; high- grade = 1.5% RR of CHF (rela/ve to placebo): all- grade 1.81; high- grade 3.3 Richards CJ, et al. JCO 2011
31 Real world seung common if you look for it. Hall P, et al. JACC: Heart Failure 2013
32 Cardiac Toxicity Management Kollmannsberger et al. CUAJ 2007
33 ECG Changes TKIs including suni/nib have poten/al to increase QTc in dose dependent manner However meta- analysis data on >5,000 pa/ents demonstrated <2.3% grade 3 and <0.1% Torsade in suni/nib exposed pa/ents. Even lower for pazopanib (<0.3% grade 3) Risk- stra/fied monitoring and evalua/on of concomitant medica/ons is warranted. Bello C, et al. Clin Cancer Res 2009; Ghatalia P, et al. BJC 2015
34 Click to edit Master /tle style Summary The treatment landscape of metasta/c RCC has evolved greatly over the last 10 years Median survivals measured in years rather than months Evolu/on con/nues now with immunotherapeu/cs Side effect management and treatment individualiza/on is crucial Mul/- disciplinary care of toxici/es is increasingly important
35 Click to edit Master /(slides) Acknowledgements tle style C. Kollmannsberger G. Bjarnason
36 Click to edit Master /tle style Thank You.
David N. Robinson, MD
David N. Robinson, MD Background and Treatment of mrcc Background ~ 64,770 new cases of kidney/renal pelvis cancers will be diagnosed in the US in 2012 with an estimated 13,570 deaths [1] ~ 75% are clear-cell
More informationDose individualization of sunitinib in mrcc: Toxicity-adjusted dose or Therapeutic drug monitoring
Dose individualization of sunitinib in mrcc: Toxicity-adjusted dose or Therapeutic drug monitoring Alison Zhang 1, Peter Fox 1, Sally Coulter 4, Val Gebski 5, Bavanthi Balakrishnar 1, Christopher Liddle
More informationTreatment Algorithm and Therapy Management in mrcc. Manuela Schmidinger Medical University of Vienna Austria
Treatment Algorithm and Therapy Management in mrcc Manuela Schmidinger Medical University of Vienna Austria A Paradigm Shift in the Treatment of mrcc 1. Sunitinib 2. Sorafenib 3. Bevacizumab+IFN-alpha
More informationMetastatic renal cancer (mrcc): Evidence-based treatment
Metastatic renal cancer (mrcc): Evidence-based treatment José M. Ruiz Morales, M.D. Hospital Médica Sur April 18th, 2018 4th ESO-ESMO Latin American Masterclass in Clinical Oncology Disclosures Consulting:
More informationImmunotherapy versus targeted treatments in metastatic renal cell carcinoma: The return game?
Immunotherapy versus targeted treatments in metastatic renal cell carcinoma: The return game? Sylvie NEGRIER MD, PhD Centre Léon Bérard, Lyon Université Lyon I IMMUNOTHERAPY: A LONG AND WIDING ROAD! WHERE
More informationHave Results of Recent Randomized Trials Changed the Role of mtor Inhibitors?
Have Results of Recent Randomized Trials Changed the Role of mtor Inhibitors? Bernard Escudier Institut Gustave Roussy Villejuif, France EIKCS Lyon April 2015 What is the current role of mtor inhibitors?
More informationLinee guida terapeutiche oncologiche. Francesco Massari U.O.C. di Oncologia Medica d.u. Azienda Ospedaliera Universitaria Integrata Verona
Linee guida terapeutiche oncologiche Francesco Massari U.O.C. di Oncologia Medica d.u. Azienda Ospedaliera Universitaria Integrata Verona 1 YOUNG SPECIALIST RENAL CARE Verona, 07-08 Marzo 2014 Clinical
More informationSequencing of therapies in mrcc. Ari Hakimi MD Assistant Professor Urology Service, Department of Surgery MSKCC
Sequencing of therapies in mrcc Ari Hakimi MD Assistant Professor Urology Service, Department of Surgery MSKCC Old Paradigm Sequencing approved agents VEGF TKI Sunitinib Pazopanib Axitinib TKI TKI MTORi
More informationEvidenze cliniche nel trattamento del RCC
Criteri di scelta nel trattamento sistemico del carcinoma renale Evidenze cliniche nel trattamento del RCC Alessandro Morabito Unità Sperimentazioni Cliniche Istituto Nazionale Tumori di Napoli Napoli,
More informationNegative Trials in RCC: Where Did We Go Wrong? Can We Do Better?
Negative Trials in RCC: Where Did We Go Wrong? Can We Do Better? 9 th European Kidney Cancer Symposium, Dublin, April 2014 Tim Eisen Tim Eisen - Disclosures Company Research Support Advisory Board Trial
More informationMedical Management of Renal Cell Carcinoma
Medical Management of Renal Cell Carcinoma Lin Mei, MD Hematology-Oncology Fellow Hematology, Oncology and Palliative Care Virginia Commonwealth University Educational Objectives Background of RCC (epidemiology,
More informationMetastatic Renal Cancer Medical Treatment
Metastatic Renal Cancer Medical Treatment Bohuslav Melichar, M.D., Ph.D. Professor and Head Department of Oncology Palacký University Medical School and Teaching Hospital Olomouc, Czech Republic Peculiarities
More informationTreatment of Renal Cell Carcinoma (RCC) in the Era of Targeted Agents
Conflict of Interest Treatment of Renal Cell Carcinoma (RCC) in the Era of Targeted Agents None Patrick Medina, PharmD, BCOP Associate Professor University of Oklahoma OKC, OK Learning Objectives Epidemiology
More informationToxicity as a Biomarker
Toxicity as a Biomarker Frede Donskov, M.D., PhD Chair, Danish Renal Cancer Group, DARENCA Aarhus University Hospital Denmark Thirteenth International COI Research funding from Novartis, GSK, Pfizer and
More informationNew strategies and future of target therapy in advanced kidney cancer
New strategies and future of target therapy in advanced kidney cancer VHL Gene Inactivation VHL Complex Disrupted VHL Protein HIF1-a, HIF2-a Accumulation VEGF PDGF TGF-α, CXCR4 Angiogenesis Endothelial
More informationTiming of targeted therapy in patients with low volume mrcc. Eli Rosenbaum Davidoff Cancer Center Beilinson Hospital
1 Timing of targeted therapy in patients with low volume mrcc Eli Rosenbaum Davidoff Cancer Center Beilinson Hospital 2 Wont be discussing: Symptomatic patients High volume disease Rapidly growing metastases
More informationWinship Cancer Institute of Emory University Neoadjuvant Systemic Therapy in Metastatic Renal Cell Carcinoma Patients
Winship Cancer Institute of Emory University Neoadjuvant Systemic Therapy in Metastatic Renal Cell Carcinoma Patients Bradley Carthon, MD, PhD Assistant Professor, Genitourinary Medical Oncology Winship
More informationCytoreductive Nephrectomy
Cytoreductive Nephrectomy Stephen H. Culp, M.D., Ph.D. Assistant Professor, Department of Urology Outline The Historics of CN The current status of CN The importance of patient selection Cytoreductive
More informationSecond - Line Debate: Axitinib
Second - Line Debate: Axitinib Alain Ravaud, MD PhD Bordeaux, France DISCLOSURES Member of Global, European and/or French advisory board in RCC and/or GU tumors for Pfizer, Novartis, GSK, Roche, BMS, Merck.
More informationpan-canadian Oncology Drug Review Stakeholder Feedback on a pcodr Request for Advice Axitinib (Inlyta) for Metastatic Renal Cell Carcinoma
pan-canadian Oncology Drug Review Stakeholder Feedback on a pcodr Request for Advice Axitinib (Inlyta) for Metastatic Renal Cell Carcinoma Pfizer Canada Inc. June 29, 2017 3 Stakeholder Feedback on a pcodr
More informationThe Therapeutic Landscape in Advanced Renal Cell Carcinoma
The Therapeutic Landscape in Advanced Renal Cell Carcinoma Cora Sternberg, MD, FACP Chairman, Department of Medical Oncology San Camillo-Forlanini Hospital Rome, Italy What best describes the change in
More informationClinical Biomarker in Kidney Cancer. Maria Nirvana Formiga, M.D., Ph.D.
Clinical Biomarker in Kidney Cancer Maria Nirvana Formiga, M.D., Ph.D. Disclosures I am on the Speaker s Bureau with Pfizer and Bayer Clinical trials of BMS and Pfizer Kidney Cancer 70% new cases in developed
More informationMedical treatment of metastatic renal cell carcinoma (mrcc) in the elderly ( 65y): Position of a SIOG Taskforce
Medical treatment of metastatic renal cell carcinoma (mrcc) in the elderly ( 65y): Position of a SIOG Taskforce Medical treatment of metastatic RCC in the elderly ( 65y): Members of the SIOG Taskforce
More informationRenal Cell Cancer: Present and Future. Bernard Escudier, Gustave Roussy
Renal Cell Cancer: Present and Future Bernard Escudier, Gustave Roussy [HKIOF May 2017] Sponsored by Bristol- Myers Squibb OPDIVO Hong Kong prescribing information is available upon request Disclosures
More informationEmerging Biomarkers of VEGF and mtor Inhibitors in 2015
Emerging Biomarkers of VEGF and mtor Inhibitors in 2015 Laurence Albiges Institut Gustave Roussy, France Fourteenth International Kidney Cancer Symposium Miami, Florida, USA November 6-7, 2015 www.kidneycancersymposium.com
More informationDevelopping the next generation of studies in RCC
Developping the next generation of studies in RCC Bernard Escudier Institut Gustave Roussy Villejuif, France Disclosure Information Advisory/Consultancy Role Pfizer, Exelixis, Novartis, BMS, Bayer, Roche,
More informationTargeted Therapy in Advanced Renal Cell Carcinoma
Targeted Therapy in Advanced Renal Cell Carcinoma Brian I. Rini, M.D. Department of Solid Tumor Oncology Glickman Urologic and Kidney Institute Cleveland Clinic Taussig Cancer Institute Cleveland, Ohio
More informationAntiangiogenic Agents in NSCLC Where are we? Which biomarkers? VEGF Is the Only Angiogenic Factor Present Throughout the Tumor Life Cycle
Antiangiogenic Agents in NSCLC Where are we? Which biomarkers? Martin Reck Department e t of Thoracic c Oncology ogy Hospital Grosshansdorf Germany VEGF Is the Only Angiogenic Factor Present Throughout
More informationCLINICAL CHALLENGES IN METASTATIC RENAL CELL CARCINOMA: THE RIGHT THERAPY FOR THE RIGHT PATIENT
Daniel Heng, MD, MPH, FRCPC @DrDanielHeng Chair GU Tumour Group, Tom Baker Cancer Centre Clinical Professor, University of Calgary CLINICAL CHALLENGES IN METASTATIC RENAL CELL CARCINOMA: THE RIGHT THERAPY
More informationTargeted and immunotherapy in RCC
Targeted and immunotherapy in RCC Treatment options Surgery (radical VS partial nephrectomy) Thermal ablation therapy Surveillance Immunotherapy Molecular targeted therapy Molecular targeted therapy Targeted
More informationUPDATE FROM ASCO GU FEBRUARY 2018, SAN FRANCISCO, USA. Prof. David Pfister University Hospital of Cologne Germany RENAL CELL CARCINOMA
UPDATE FROM ASCO GU FEBRUARY 2018, SAN FRANCISCO, USA Prof. David Pfister University Hospital of Cologne Germany RENAL CELL CARCINOMA DISCLAIMER Please note: The views expressed within this presentation
More informationSergio Bracarda MD. Head, Medical Oncology Department of Oncology AUSL-8 Istituto Toscano Tumori (ITT) San Donato Hospital Arezzo, Italy
Sergio Bracarda MD Head, Medical Oncology Department of Oncology AUSL-8 Istituto Toscano Tumori (ITT) San Donato Hospital Arezzo, Italy Ninth European International Kidney Cancer Symposium Dublin 25-26
More informationI Kid(ney) You Not: Updates on Renal Cell Carcinoma
Disclosures I Kid(ney) You Not: Updates on Renal Cell Carcinoma Nothing to disclose Renee McAlister, PharmD, BCOP Clinical Pharmacist, GU/Melanoma Vanderbilt Ingram Cancer Center September 29, 2018 Objectives
More informationA Review in the Treatment Options for Renal Cell Cancer
A Review in the Treatment Options for Renal Cell Cancer Ali McBride, PharmD, MS BCPS, BCOP Clinical Coordinator Hematology/Oncology Department of Pharmacy The University of Arizona Cancer Center RENAL
More informationInnovaciones en el tratamiento del ca ncer renal. Enrique Grande
Innovaciones en el tratamiento del ca ncer renal Enrique Grande The enriched inflammatory environment of RCC Chen Z, et al. Nat Rev Cancer 2014 Available agents are expanding across the three eras of arcc
More informationSequential Therapy in Renal Cell Carcinoma*
Sequential Therapy in Renal Cell Carcinoma* Bernard Escudier, MD, Marine Gross Goupil, MD, Christophe Massard, MD, and Karim Fizazi, MD, PhD Because of the recent approval of several drugs for the treatment
More informationLa revolución de la inmunoterapia: dónde la posicionamos? Javier Puente, MD, PhD
La revolución de la inmunoterapia: dónde la posicionamos? Javier Puente, MD, PhD Hospital Universitario Clinico San Carlos Medical Oncology Department Thoracic & Urological Cancer Unit Complutense University
More informationWhat can we expect from running phase III trials: will all of them alter the current treatment algorithm?
What can we expect from running phase III trials: will all of them alter the current treatment algorithm? 8 th European International Kidney Cancer Symposium Budapest, May 2013 Martin Gore PhD FRCP Royal
More informationRenal Cell Carcinoma: Systemic Therapy Progress and Promise
Renal Cell Carcinoma: Systemic Therapy Progress and Promise Michael B. Atkins, M.D. Deputy Director, Lombardi Comprehensive Cancer Ctr Georgetown University Medical Center Everolimus Rini, Campbell, Escudier.
More informationIntegrating novel therapy in advanced renal cell carcinoma
Integrating novel therapy in advanced renal cell carcinoma Tian Zhang, MD Assistant Professor of Medicine GU Oncology Duke Cancer Institute March 11, 2017 Disclosures Research Funding Janssen Pfizer Consultant
More informationAtezolizumab Adjuvant Study: Medical Oncologist Perspective. Sumanta K. Pal, MD City of Hope Comprehensive Cancer Center
Atezolizumab Adjuvant Study: Medical Oncologist Perspective Sumanta K. Pal, MD City of Hope Comprehensive Cancer Center Trial overview Key issues Outline Challenges with neoadjuvant therapy Placebo control
More informationSurgical Management of Metastatic and Locally Recurrent Kidney Cancer: Does it Make Sense?
Surgical Management of Metastatic and Locally Recurrent Kidney Cancer: Does it Make Sense? Philippe E. Spiess, MD, FACS Associate Member Department of GU Oncology Department of Tumor Biology Moffitt Cancer
More informationWhy was HOPE 205 a Positive After Years of Negative Studies?
Why was HOPE 205 a Positive After Years of Negative Studies? Prof. Dr. med. Viktor Grünwald Klinik für Hämatologie, Hämostaseologie, Onkologie und Stammzelltransplantation Why do we pursue combinations?
More informationInmunoterapia en cáncer renal metastásico: redefiniendo el tratamiento de segunda línea
Inmunoterapia en cáncer renal metastásico: redefiniendo el tratamiento de segunda línea Daniel Castellano Oncología Médica. Unidad de Tumores Genito-Urinarios Hospital Universitario 12 de Octubre I + 12
More informationThe Use of Inhibitors of Angiogenesis in Patients with Inoperable Locally Advanced or Metastatic Renal Cell Cancer: Guideline Recommendations
Evidence-Based Series #3-8-4: Section 1 The Use of Inhibitors of Angiogenesis in Patients with Inoperable Locally Advanced or Metastatic Renal Cell Cancer: Guideline Recommendations S. Hotte, T. Waldron,
More informationPrognostic Factors: Does It Really Matter if New Drugs for Targeted Therapy Will Be Used?
european urology supplements 8 (2009) 478 482 available at www.sciencedirect.com journal homepage: www.europeanurology.com Prognostic Factors: Does It Really Matter if New Drugs for Targeted Therapy Will
More informationComplete Remission is a Reachable Goal in mrcc L. Albiges Institut Gustave Roussy
Complete Remission is a Reachable Goal in mrcc L. Albiges Institut Gustave Roussy Is complete remission an achievable goal in mrcc? Lessons from observation Lessons from immunotherapy Current status in
More informationADVISORY COMMITTEE BRIEFING MATERIALS: AVAILABLE FOR PUBLIC RELEASE
Tivozanib Hydrochloride in Advanced Renal Cell Carcinoma ADVISORY COMMITTEE BRIEFING MATERIALS: AVAILABLE FOR PUBLIC RELEASE AVEO PHARMACEUTICALS, INC. 75 Sidney Street Cambridge, MA 02139 Tel: (617) 299-5000
More informationCLINICAL POLICY Department: Medical Management Document Name: Inlyta Reference Number: NH.PHAR.100 Effective Date: 05/12
Page: 1 of 5 IMPORTANT REMINDER This Clinical Policy has been developed by appropriately experienced and licensed health care professionals based on a thorough review and consideration of generally accepted
More information12 AISF Special Conference Sorafenib: magnitude of benefit, side effects and stopping rules 9 years after approval
12 AISF Special Conference Sorafenib: magnitude of benefit, side effects and stopping rules 9 years after approval ARMANDO SANTORO Roma 10-6-2016 SORAFENIB APPROVAL 29 OCTOBER 2007 Marketing authorization
More informationTherapeutic effects and associated adverse events of multikinase inhibitors in metastatic renal cell carcinoma: A meta-analysis
EXPERIMENTAL AND THERAPEUTIC MEDICINE 9: 2275-2280, 2015 Therapeutic effects and associated adverse events of multikinase inhibitors in metastatic renal cell carcinoma: A meta-analysis QINXIANG TAN 1*,
More informationManagement of High Risk Renal Cell Carcinoma
Management of High Risk Renal Cell Carcinoma Peter E. Clark, MD Professor and Chair, Department of Urology Carolinas HealthCare System Chair, Urologic Oncology Levine Cancer Institute October 14, 2017
More informationIndication for- and timing of cytoreductive nephrectomy Kidney- and bladder cancer: Immunotherapy
Indication for- and timing of cytoreductive nephrectomy Kidney- and bladder cancer: Immunotherapy Axel Bex, MD, PhD The Netherlands Cancer Institute Oslo, September 4, 2018 Financial and Other Disclosures
More informationCurrent experience in immunotherapy for metastatic renal cell carcinoma
Current experience in immunotherapy for metastatic renal cell carcinoma Axel Bex, MD, PhD The Netherlands Cancer Institute FOIU, Tel Aviv, 3 July 2018 Financial and Other Disclosures Off-label use of drugs,
More informationTratamiento adyuvante y neoadyuvante del cáncer renal en Xavier Garcia del Muro Solans Institut Català d Oncologia Hospitalet.
Tratamiento adyuvante y neoadyuvante del cáncer renal en 2017 Xavier Garcia del Muro Solans Institut Català d Oncologia Hospitalet. Barcelona Pronóstico del CR mediante un sistema integrado en 468 pts
More informationNEXT GENERATION DRUGS IN KIDNEY CANCER. Dr Aine O Reilly Karolinska Institutet Stockholm, Sweden
NEXT GENERATION DRUGS IN KIDNEY CANCER Dr Aine O Reilly Karolinska Institutet Stockholm, Sweden KIDNEY CANCER SUBTYPES Papillary Type 1 and 2 Medullary Collecting duct Chromophobe Translocation Clear cell
More informationAxitinib in renal cell carcinoma: now what do we do?
Renal Cell Carcinoma Axitinib in renal cell carcinoma: now what do we do? Ian D. Davis Monash University Eastern Health Clinical School, Level 2, Box Hill, Victoria 3128, Australia Correspondence to: Ian
More informationImmunotherapy for Renal Cell Carcinoma. James Larkin
Immunotherapy for Renal Cell Carcinoma James Larkin Disclosures Institutional research support: BMS, MSD, Novartis, Pfizer Consultancy (all non-remunerated): Eisai, BMS, MSD, GSK, Pfizer, Novartis, Roche/Genentech
More informationSequential Use of the Tyrosine Kinase Inhibitors Sorafenib and Sunitinib in Metastatic Renal Cell Carcinoma: A Retrospective Outcome Analysis
available at www.sciencedirect.com journal homepage: www.europeanurology.com Kidney Cancer Sequential Use of the Tyrosine Kinase Inhibitors Sorafenib and Sunitinib in Metastatic Renal Cell Carcinoma: A
More informationASCO 2012 Genitourinary tumors
ASCO 2012 Genitourinary tumors Post ASCO Bern 14-06-2012 Dr. med. Richard Cathomas leitender Arzt Onkologie, KSGR, Chur Renal cell cancer Changes in first line treatment? Prostate cancer 3 positive phase
More informationA Korean multi-center, real-world, retrospective study of first-line pazopanib in unselected patients with metastatic renal clear-cell carcinoma
Kim et al. BMC Urology (2016) 16:46 DOI 10.1186/s12894-016-0163-5 RESEARCH ARTICLE Open Access A Korean multi-center, real-world, retrospective study of first-line pazopanib in unselected patients with
More informationPrognostic Factors for mrcc: Relevance in Clinical Practice
Prognostic Factors for mrcc: Relevance in Clinical Practice Daniel Heng MD MPH FRCPC Chair, GU Tumor Group Tom Baker Cancer Center University of Calgary Prognostic Factors Patient Factors Performance Status
More informationpan-canadian Oncology Drug Review Final Clinical Guidance Report Axitinib (Inlyta) for metastatic Renal Cell Carcinoma March 7, 2013
pan-canadian Oncology Drug Review Final Clinical Guidance Report Axitinib (Inlyta) for metastatic Renal Cell Carcinoma March 7, 2013 DISCLAIMER Not a Substitute for Professional Advice This report is primarily
More informationChemotherapy and Immunotherapy in Combination Non-Small Cell Lung Cancer (NSCLC)
Chemotherapy and Immunotherapy in Combination Non-Small Cell Lung Cancer (NSCLC) Jeffrey Crawford, MD George Barth Geller Professor for Research in Cancer Co-Program Leader, Solid Tumor Therapeutics Program
More informationRiunione Monotematica A.I.S.F The future of liver diseases. HEPATIC NEOPLASMS The challenge for new drugs
Riunione Monotematica A.I.S.F. 2016 The future of liver diseases Milan 13 th -15 th October 2016 Centro Congressi Fondazione Cariplo HEPATIC NEOPLASMS The challenge for new drugs Massimo Iavarone Gastroenterology
More informationpan-canadian Oncology Drug Review Final Clinical Guidance Report Nivolumab (Opdivo) for Metastatic Renal Cell Carcinoma September 1, 2016
pan-canadian Oncology Drug Review Final Clinical Guidance Report Nivolumab (Opdivo) for Metastatic Renal Cell Carcinoma September 1, 2016 DISCLAIMER Not a Substitute for Professional Advice This report
More informationFifteenth International Kidney Cancer Symposium
The following presentation should not be regarded as an endorsement of a particular product/drug/technique by the speaker. The presentation topics were assigned to the speakers by the scientific committee
More informationMultidisciplinary approach for renal cell carcinoma Axel Bex, MD, PhD The Netherlands Cancer Institute
Multidisciplinary approach for renal cell carcinoma Axel Bex, MD, PhD The Netherlands Cancer Institute 20 April, Antalya, Turkey RCC European Union 60.000 new diagnoses/year 26.000 Cancer related deaths
More informationReference No: Author(s) Approval date: June Committee. Operational Date: July Review:
Reference No: Title: Author(s) Systemic anti-cancer therapy (SACT) guidelines for renal cell cancer Dr Alison Clayton Consultant Medical Oncologist & Dr Jane Hurwitz Consultant Medical Oncologist, Cancer
More informationAngiogenesis and tumor growth
Anti-angiogenic agents: where we are? Martin Reck Department of Thoracic Oncology Hospital Grosshansdorf Germany Angiogenesis and tumor growth Journal of experimental Medicine 1972; 133: 275-88 1 Angiogenesis
More informationRevisione Oral Abstracts
Revisione Oral Abstracts Francesco Massari Oncologia Medica Azienda Ospedaliero Universitaria di Bologna Policlinico S. Orsola-Malpighi UPDATES and NEWS from the Genitourinary Cancers Symposium - Milano,
More informationManagement del paziente dializzato Roberto Sabbatini Azienda Ospedaliero Universitaria Policlinico di Modena
Management del paziente dializzato Roberto Sabbatini Azienda Ospedaliero Universitaria Policlinico di Modena AIOM incontra SIN Milano 9 marzo 2017 Renal Cell Carcinoma and Renal Impairment Up to 15% of
More informationThe Current Champion: Angiogenesis inhibitors
The Current Champion: Angiogenesis inhibitors Baek-Yeol RYOO University of Ulsan College of Medicine ASAN Medical Center Dept. of Oncology Seoul, Korea Survival probability Sorafenib: Overall Survival
More informationCharacterization of Patients with Poor-
Characterization of Patients with Poor- Risk Metastatic Renal Cell Carcinoma Hamieh L 1 *, McKay RR 1 *, Lin X 2, Simantov R 2, Choueiri TK 1 *Equal contributions 1 Dana-Farber Cancer Institute, Boston,
More informationVEGF-Inhibitors in NSCLC. Martin Reck Department of Thoracic Oncology Hospital Grosshansdorf Germany
VEGF-Inhibitors in NSCLC Martin Reck Department of Thoracic Oncology Hospital Grosshansdorf Germany Conflicts of interest Advisory Board: AstraZeneca Bristol-Myers Squibb Daiichi Sankyo Eli Lilly Merck
More informationA Quality Initiative of the Program in Evidence-Based Care (PEBC), Cancer Care Ontario (CCO)
Guideline 3-8-4 Version 2 A Quality Initiative of the Program in Evidence-Based Care (PEBC), Cancer Care Ontario (CCO) The Use of Targeted Therapies in Patients with Inoperable Locally Advanced or Metastatic
More informationAngiogenesis Targeted Therapies in Renal Cell Carcinoma
Angiogenesis Targeted Therapies in Renal Cell Carcinoma John S. Lam, MD Department of Urology David Geffen School of Medicine University of California-Los Angeles Patient Case CC: Abdominal pain VS: T
More informationREAL WORLD PRACTICE: ADJUVANT THERAPY READY FOR PRIME TIME? PRO
REAL WORLD PRACTICE: ADJUVANT THERAPY READY FOR PRIME TIME? PRO Alain Ravaud, MD.PhD Bordeaux. France DISCLOSURES Consultant for: Pfizer, Novartis, GlaxoSmithKline, Roche, Bristol-Myers Squibb Institutional
More informationRenal Cell Carcinoma Updated February 2016 by Dr. Safiya Karim (PGY 5 Medical Oncology Resident, University of Toronto)
Renal Cell Carcinoma Updated February 2016 by Dr. Safiya Karim (PGY 5 Medical Oncology Resident, University of Toronto) Reviewed by Dr. Nimira Alimohamed (Staff Medical Oncologist, University of Calgary)
More informationIntegration of Surgery And Systemic Therapy In The Treatment of
Integration of Surgery And Systemic Therapy In The Treatment of Advanced Renal Cell Carcinoma Christopher G. Wood, M. D., FACS Professor and Deputy Chairman Douglas E. Johnson, M. D. Professorship In Urology
More informationFifteenth International Kidney Cancer Symposium November 4-5, 2016 Marriott Miami Biscayne Bay, Miami, Florida, USA
The following presentation should not be regarded as an endorsement of a particular product/drug/technique by the speaker. The presentation topics were assigned to the speakers by the scientific committee
More informationManagement of advanced kidney cancer: Canadian Kidney Cancer Forum (CKCF) consensus update 2017
consensus statement Management of advanced kidney cancer: Canadian Kidney Cancer Forum (CKCF) consensus update 2017 This review is CUA-accredited for Section 3 credits of the MOC Program of the RCPSC.
More informationCheckpointinhibitoren in der Uro-Onkologie. Carsten Grüllich
Checkpointinhibitoren in der Uro-Onkologie Carsten Grüllich 07.02.15 T-cell Aktivierung und Regulation T cell Costimulation Recognition MHC I Peptide b2m mrna Tumorantigen Tumor Pardoll Nature Rev Cancer
More informationMetastatic Renal Cell Cancer - Therapeutic Challanges 2011
Metastatic Renal Cell Cancer - Therapeutic Challanges 2011 Brian I. Rini, M.D. Department of Solid Tumor Oncology Cleveland Clinic Taussig Cancer Institute Glickman Urologic and Kidney Institute Cleveland,
More informationNivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mrcc): Results of a phase I trial
Nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mrcc): Results of a phase I trial H. Hammers, E.R. Plimack, J.R. Infante, M.S. Ernstoff, B. Rini, D.F. McDermott, A. Razak,
More informationCANCER UROLOGY VOL. 12. P. S. Borisov 1, M. I. Shkol nik 2, R. V. Orlova 3, P. A. Karlov 1 DOI: /
CANCER UROLOGY 3 6 VOL. The use of targeted therapies and selection of the optimal treatment sequence in heterogeneous population of patients with metastatic kidney cancer. Results of retrospective study
More informationRenal Cell Carcinoma: Status of Medical and Surgical Therapy. Ronald M. Bukowski Emeritus Physician Cleveland Clinic Foundation
Renal Cell Carcinoma: Status of Medical and Surgical Therapy Ronald M. Bukowski Emeritus Physician Cleveland Clinic Foundation Metastatic Renal Cell Carcinoma: Evolution of Current Therapeutic Approaches
More informationThe Really Important Questions Current Immunotherapy Trials are Not Answering
The Really Important Questions Current Immunotherapy Trials are Not Answering David McDermott, MD Beth Israel Deaconess Medical Center Dana Farber/Harvard Cancer Center Harvard Medical School PD-1 Pathway
More informationINTEGRATION OF SURGERY AND SYSTEMIC THERAPY FOR ADVANCED RENAL CELL CARCINOMA IN THE TARGETED THERAPY ERA
INTEGRATION OF SURGERY AND SYSTEMIC THERAPY FOR ADVANCED RENAL CELL CARCINOMA IN THE TARGETED THERAPY ERA Dr. Michael J. Metcalfe PGY-4 Department of Urologic Sciences University of British Columbia October
More informationImmunotherapy for the Treatment of Kidney and Bladder Cancer
Immunotherapy for the Treatment of Kidney and Bladder Cancer Alan J. Koletsky, MD Genitourinary Cancer Research Program, Lynn Cancer Institute Clinical Asistant Professor of Biomedical Science The Charles
More informationKidney Cancer Session
New Frontiers in Urologic Oncology September 12 th, 2015 Kidney Cancer Session Moderator: Philippe E. Spiess, M.D. Invited Faculty Members: Wade J. Sexton, MD Jeremiah J. Morrissey, PhD Agenda for Session
More informationASCO 2011 Genitourinary Cancer
ASCO 2011 Genitourinary Cancer Expanding Options for Chronic Diseases? Walter Stadler, MD, FACP University of Chicago Disclosures (All Non-University &/or Financial Dealings with Potential, Real, or Perceived
More informationAVEO and Astellas Announce TAURUS Patient Preference Clinical Study Comparing Tivozanib with Sunitinib in First-Line Kidney Cancer
FOR IMMEDIATE RELEASE AVEO and Astellas Announce TAURUS Patient Preference Clinical Study Comparing Tivozanib with Sunitinib in First-Line Kidney Cancer Study designed to build upon safety profile demonstrated
More information17/01/2017. Use of kinase inhibitors in oncology practice. Multikinase inhibitors. Sunitinib (Sutent )targets. Many more sunitinib kinase targets (42)
Multikinase inhibitors Use of kinase inhibitors in oncology practice Prof Jacques De Grève, UZ Brussel Inhibit multiple intracellular and cell surface kinases Tyrosine or serine-threonine kinases Multitargeting
More informationThe plan. Overview of clinical trials Current clinical trials in renal cancer Future treatment of renal cancer
Relevant disclosure Bayer - consultancy GSK research funding, consultancy, speaker honoraria Novartis research funding Pfizer research funding, consultancy Roche / Genentech research funding, consultancy
More informationThis is the fourth report from the Kidney Cancer Research
CONSENSUS STATEMENT Management of advanced kidney cancer: Canadian Kidney Cancer Forum 2013 Consensus Update Canadian Kidney Cancer Forum 2013 Scott North, MD, FRCPC; Naveen Basappa, MD; Georg Bjarnason,
More informationOncology A Phase II Study of Presurgical Sunitinib in Patients with Metastatic Clear-cell Renal Carcinoma and the Primary Tumor In Situ
Oncology A Phase II Study of Presurgical Sunitinib in Patients with Metastatic Clear-cell Renal Carcinoma and the Primary Tumor In Situ Axel Bex, Christian Blank, Wim Meinhardt, Harm van Tinteren, Simon
More informationCurrent Status of Studies on Targeted Therapy for Renal Cell Carcinoma
294 Chin J Clin Oncol (2008) 5: 294~298 DOI 10.1007/s11805-008-0294-x Current Status of Studies on Targeted Therapy for Renal Cell Carcinoma Shaoqi Wang 1 Shaoxiang Wang 2 Juan Wang 1 1 Department of Oncology,
More informationRenal Cell Cancer. Clinical case study 1 & 2. Petri Bono MD PhD Helsinki University Hospital Helsinki, Finland
Renal Cell Cancer Clinical case study 1 & 2 Petri Bono MD PhD Helsinki University Hospital Helsinki, Finland 1 Case study 1 - RCC and Lung Metastases Case study 1: Patient History Male, 63 years old Mild
More informationCytokines: Interferons, Interleukins and Beyond. Michael B. Atkins, MD Georgetown-Lombardi Comprehensive Cancer Center
Cytokines: Interferons, Interleukins and Beyond Michael B. Atkins, MD Georgetown-Lombardi Comprehensive Cancer Center Disclosures Advisory Boards: Bristol-Myers Squibb,Amgen, Novartis, Alkermes, Infinity,
More information